DGCR8 antibody (N-Term)

Catalog No. ABIN2776557

Product Details anti-DGCR8 Antibody

Target: DGCR8 (DiGeorge Syndrome Critical Region Gene 8 (DGCR8))

Binding Specificity: N-Term

Reactivity: Human, Mouse, Rat, Cow, Dog, Horse, Guinea Pig, Rabbit, Zebrafish (Danio rerio)

Host: Rabbit

Clonality: Polyclonal

Conjugate: This DGCR8 antibody is un-conjugated

Application: Western Blotting (WB), Immunohistochemistry (IHC)

Sequence: DKKDEENELD QEKRVEYAVL DELEDFTDNL ELDEEGAGGF TAKAIVQRDR

Predicted Reactivity: Cow: 85%, Dog: 100%, Guinea Pig: 100%, Horse: 93%, Human: 100%, Mouse: 100%, Rabbit: 93%, Rat: 100%, Zebrafish: 77%

Characteristics: This is a rabbit polyclonal antibody against DGCR8. It was validated on Western Blot using a cell lysate as a positive control.

Purification: Affinity Purified

Immunogen: The immunogen is a synthetic peptide directed towards the N terminal region of human DGCR8

Application Details

Application Notes: Optimal working dilutions should be determined experimentally by the investigator.

Comment:

Antigen size: 773 AA

Restrictions: For Research Use only

Handling

Format: Liquid

Concentration: Lot specific

Buffer: Liquid. Purified antibody supplied in 1x PBS buffer with 0.09 % (w/v) sodium azide and 2 % sucrose.

Preservative: Sodium azide

Precaution of Use: This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Handling Advice: Avoid repeated freeze-thaw cycles.

Storage: -20 °C

Storage Comment: For short term use, store at 2-8°C up to 1 week. For long term storage, store at -20°C in small aliquots to prevent freeze-thaw cycles.

References for anti-DGCR8 antibody (ABIN2776557)

Belair, Paikari, Moltzahn, Shenoy, Yau, DallEra, Simko, Benz, Blelloch: "DGCR8 is essential for tumor progression following PTEN loss in the prostate." in: EMBO reports, Vol. 16, Issue 9, pp. 1219-32, (2015) (PubMed).

Van Duyne, Guendel, Klase, Narayanan, Coley, Jaworski, Roman, Popratiloff, Mahieux, Kehn-Hall, Kashanchi: "Localization and sub-cellular shuttling of HTLV-1 tax with the miRNA machinery." in: PLoS ONE, Vol. 7, Issue 7, pp. e40662, (2012) (PubMed).

Kye, Neveu, Lee, Zhou, Steen, Sahin, Kosik, Silva: "NMDA mediated contextual conditioning changes miRNA expression." in: PLoS ONE, Vol. 6, Issue 9, pp. e24682, (2011) (PubMed).

Target Details for DGCR8

Target: DGCR8 (DiGeorge Syndrome Critical Region Gene 8 (DGCR8))

Alternative Name: DGCR8 (DGCR8 Products)

Synonyms: MGC78846 antibody, DGCR8 antibody, gy1 antibody, dgcrk6 antibody, C22orf12 antibody, DGCRK6 antibody, Gy1 antibody, pasha antibody, D16H22S1742E antibody, D16H22S788E antibody, D16Wis2 antibody, N41 antibody, Vo59c07 antibody, si:ch211-106a19.4 antibody, wu:fc23f08 antibody, wu:fc38f06 antibody, DGCR8 microprocessor complex subunit L homeolog antibody, DiGeorge syndrome critical region gene 8 antibody, DGCR8 microprocessor complex subunit antibody, DGCR8, microprocessor complex subunit antibody, microRNA 3618 antibody, dgcr8.L antibody, DGCR8 antibody, dgcr8 antibody, Dgcr8 antibody, MIR3618 antibody

Background: DGCR8 contains 2 DRBM (double-stranded RNA-binding) domains and 1 WW domain. It may play a part in the etiology of the velocardiofacial/DiGeorge syndrome (VCFS/DGS), a developmental disorder characterized by structural and functional palate anomalies, conotruncal cardiac malformations, immunodeficiency, hypocalcemia, and typical facial anomalies.
Alias Symbols: C22orf12, DGCRK6, Gy1, pasha
Protein Interaction Partner: MEOX2, PYCRL, DROSHA, RAE1, MAPK1, PRMT1, ERH, CDKN2A, BMI1, SRPK2, SRPK1, CDT1, NAT10, PLEK2, RPRD2, MAPRE2, PRPF4, FLII, APP, CUL3, DDX17, HNRNPR, NCL, ILF3, HSPA8, HSPA5, HNRNPU, HNRNPH1, FUS, DHX9, DDX5,
Protein Size: 773

Molecular Weight: 85 kDa

Gene ID: 54487

NCBI Accession: NM_022720, NP_073557

UniProt: Q8WYQ5

Pathways: Regulatory RNA Pathways